CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on May 10, 2024
MAXIM GROUP LLC
300 Park Avenue, 16th Floor
New York, New York 10022
May 10, 2024
VIA EDGAR CORRESPONDENCE
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | Aethlon Medical, Inc. |
|
Registration Statement on Form S-1, as amended | ||
File No. 333-278188 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, the underwriter, hereby request that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced registration statement on Form S-1 (the “Registration Statement”) to become effective at 9:00 a.m., Eastern time, on Tuesday, May 14, 2024, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated April 25, 2024 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned, as underwriter, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. If you require any additional information with respect to this letter, please contact M. Ali Panjwani at (212) 326-0820 of Pryor Cashman LLP.
Very truly yours,
MAXIM GROUP LLC
By: /s/ Ritesh M. Veera |
cc: | M. Ali Panjwani, Esq. |
Pryor Cashman LLP |